PMC9132536_01
Case 1: MRI scan of a female patient with a recurrent basal cell carcinoma adjacent to the caruncle of the right eye, showing no intra-orbital invasion.
dic-2022-3-8_g001.jpg
PMC9132536_01_dic-2022-3-8_g001.jpg
f1-dic-2022-3-8
No significant laboratory abnormalities were identified, and magnetic resonance imaging (MRI) was negative for intraorbital invasion (Figure 1).
Case 1: Clinical presentation of a basal cell carcinoma in a female patient: (a) pre-treatment, (b) at 1 month (clinical response) and (c) at 1 year (continued remission) after treatment with sonidegib 200 mg/day (for 9 months).
dic-2022-3-8_g002.jpg
PMC9132536_01_dic-2022-3-8_g002.jpg
f2-dic-2022-3-8
Tumour evolution is shown in Figure 2.
PMC9132536_02
Case 2: Clinical presentation of a metatypical basal cell carcinoma with a mixed nodular and infiltrative pattern in a male patient: (a) pre-treatment and (b) after 6 months of treatment with sonidegib 200 mg/day.
dic-2022-3-8_g003.jpg
PMC9132536_02_dic-2022-3-8_g003.jpg
f3-dic-2022-3-8
Improvement was evident after 2 months and, by 6 months, a complete clinical response was achieved (Figure 3).
PMC9132536_03
Case 3: Gorlin syndrome lesions on the forehead of the patient: (a) pre-treatment and (b) after 4 months of treatment with sonidegib 200 mg/day.
dic-2022-3-8_g004.jpg
PMC9132536_03_dic-2022-3-8_g004.jpg
f4-dic-2022-3-8
In September 2021, after 4 months of sonidegib treatment, there was a decrease in the number and size of the lesions (Figure 4).
PMC9132536_04
PMC9132536_05
PMC9132536_06